72 results about "Arachnoid Membrane" patented technology

Methods, devices and systems for draining fluid from the eye and / or for reducing intraocular pressure. A passageway (e.g., an opening, puncture or incision) is formed in the lamina cribosa or elsewhere to facilitate flow of fluid from the posterior chamber of the eye to either a) a subdural location within the optic nerve or b) a location within the subarachnoid space adjacent to the optic nerve. Fluid from the posterior chamber then drains into the optic nerve or directly into the subarachnoid space, where it becomes mixed with cerebrospinal fluid. In some cases, a tubular member (e.g., a shunt or stent) may be implanted in the passageway. A particular shunt device and shunt-introducer system is provided for such purpose. A vitrectomy or vitreous liquefaction procedure may be performed to remove some or all of the vitreous body, thereby facilitating creation of the passageway and / or placement of the tubular member as well as establishing a route for subsequent drainage of aqueous humor from the anterior chamber, though the posterior chamber and outwardly though the passageway where it becomes mixed with cerebrospinal fluid.

The cerebrospinal fluid and intracranial pressure are two major reasons why central nervous system is so vulnerable to injuries. A composition and method for treating injured central nervous tissue, or preventing injury to central nervous system tissue is provided. The composition is comprised of a combination of colloidal osmotic agents and crystal osmotic agents. The method comprise of: a). Withdrawing cerebrospinal fluid from the subarachnoid spaces around the tissue to be treated or protected and b). Injecting the composition which is dissolved by patient's own cerebrospinal fluid into subarachnoid spaces. The treatment can be augmented with agents that suppress production of cerebrospinal fluid, or with other known neuroprotective agents.

Cerebral edema is the final common pathway for all CNS tissue injuries. The CSF is the major player for cerebral edema and the resultant blood perfusion deficit. A composition and method for treating injured central nervous tissue, or preventing injury to central nervous system tissue is provided. The composition includes two washing solutions, a first solution comprising an emulsion of oil, water, at least one osmotic agent and at least one emulsifier; the second solution comprising a pre-emulsion comprising water, oil, at least one osmotic agent, and at least one emulsifier. The method provides for withdrawing a volume of cerebrospinal fluid from the subarachnoid space and flushing the subarachnoid space with one or both washing solutions. Other materials may be added to the solutions to treat or prevent injury to nerve tissue resulting from injury or interruption of circulation.

The invention which belongs to the technical field of medicines concretely relates to a Fasudil hydrochloride hydrate and a preparation method thereof. Fasudil hydrochloride prepared in the invention which has three and a half crystal waters has the advantages of high purity, good stability, unapparent weight gain of moisture absorption in a high humidity condition and good formability. The invention also relates to an application of the hydrate in preparing drugs for improving and preventing ischemic cerebrovascular diseases caused by a plurality of reasons, such as cerebral infarction, vertebrobasilar artery insufficiency, delayed cerebrovascular disease caused by subarachnoid hemorrhage, cerebral vasospasm caused by brain surgery and interventional therapies, and transient ischemic attack.

The invention belongs to the technical field of medical treatment and discloses an analgesia method and device suitable for a patient with advanced cancer pain. The analgesia method and device suitable for the patient with advanced cancer pain are mainly used for intra-vertebral-canal dosage analgesia treatment for the patient with advanced cancer pain. The analgesia device suitable for the patient with advanced cancer pain at least comprises a detachable extracorporeal conduit fixator, a handle type subcutaneous tunneler, a silica gel conduit, an epidural puncture needle and other accessories, and is characterized in that the silica gel conduit is implanted under the skin, one end of the conduit is implanted to an epidural space or a cavum subarachnoidale, the other end of the conduit penetrates out of the skin of the belly, is connected with the detachable extracorporeal conduit fixator and is fixed to the skin of the belly through the detachable extracorporeal conduit fixator, and therefore a firm intra-vertebral-canal dosage passage is provided. The detachable extracorporeal conduit fixator is further connected with a portable extracorporeal electronic dosage pump. In this way, analgesia medicine is conveyed to the vertebral canal through the detachable extracorporeal conduit fixator and the silica gel conduit, and an efficient analgesia effect is achieved.

The invention provides a dynamic test system based on a high-simulation physical head model and a protection evaluation method. The high-simulation physical head model is established completely basedon a head anatomical structure and mechanical properties of biological tissues of each part of the head anatomical structure, so that the occurrence process of two common injuries, namely brain tissuecontusion and subarachnoid hemorrhage, can be truly represented; a skull and brain tissue relative tangential displacement measurement system, an intracranial pressure dynamic test system, a skull strain dynamic test system, a skull acceleration dynamic test system and a head overall acceleration test system are established, and six biomechanical injury indexes for evaluating the degree of craniocerebral injury can be obtained; the damage state corresponding to the head model without wearing the protective equipment is taken as a reference; based on the six mechanical damage indexes and the severity of brain tissue contusion and rupture and subarachnoid hemorrhage, mechanical damage evaluation and physiological damage evaluation are conducted on the biological protection efficiency of thehead protection equipment, and therefore comprehensive evaluation of the protection equipment is achieved.

To shield the spinal cord from an external compression, a barrier device having a self-expanding frame and covered with a non-porous elastomeric sheet is routed through either the subarachnoid or intradural space to the site of the compression through the lumen of a delivery catheter that is percutaneously inserted using an introducer needle. When the distal end of the delivery catheter is proximate the site of the compression, the barrier device is pushed out the distal end of the catheter and allowed to self-expand so as to be interposed between the compression and the spinal cord to prevent impingement.

The described invention provides a method for treating an interruption of a cerebral artery in a subarachnoid space at risk of interruption caused by brain injury in a mammal, which reduces signs or symptoms of at least one delayed complication associated with brain injury using a flowable sustained release particulate composition.

The invention describes a method for predicting or prognosticating the risk of death or vasospasm in a patient with a subarachnoid hemorrhage, which comprises the following steps: performing a clinical assessment of the patient according to the Hunt and Hess scale and the World Federation of Neurosurgeons (WFNS) scale; obtaining a computerised axial tomography image of the patient's skull; normalising the image obtained according to a standard skull template; obtaining a region corresponding to intracranial blood by segmenting the normalised image; calculating at least the following parameters of the region of cranial blood obtained: total volume, fractal dimension and surface-volume ratio; and determining the probability of death or vasospasm in the patient according to at least the parameters calculated.

The invention discloses application of the compound (I) as shown in formula (I) in preparing a pharmaceutical composition for treating cerebrovascular spasm. Animal experiments confirm that: SB-3CT has certain curative effect to CVS after SAH (subarachnoid hemorrhage), and can mitigate the thickening degree of spastic vessel walls and the lumen stenosis, thus providing a new treatment approach for CVS after SAH.

The present disclosure discusses a devices, systems and methods for transvascular, transvenous and / or transdural access, to the brain parenchyma, subarachnoid or subdural spaces. In some embodiments, the disclosed systems and methods may be used for local drug delivery, tissue biopsy, nanofluidic or microelectronic device / component delivery / insertion / implantation, in situ imaging, ablation of abnormal brain tissue and the like. Embodiments of the present disclosure include an access catheter system for extravascular procedures in the brain having an elongate, flexible tubular body, with at least one lumen extending axially there through between a proximal end, and a distal end. The access catheter system may include a side exit port and a distal end port. Further, the access catheter system may include a selective deflector positioned within the lumen configured to deflect a procedure catheter and permit a guide catheter.

The invention belongs to the technical field of medicines, in particular to an amorphous fasudil hydrochloride compound and a preparation method thereof. The amorphous fasudil hydrochloride compound obtained by the invention has the advantages of high purity, good stability, non obvious moisture-absorption weight gain even in a high humidity condition, good moldability and higher dissolution ratecompared with crystal fasudil hydrochloride. The invention also relates to application of the amorphous fasudil hydrochloride compound to the manufacture of medicines for improving and preventing cerebral ischemia-related diseases such as ischemic cerebrovascular diseases such as cerebral infarction and vertebrobasilar artery insufficiency caused by multiple reasons, delayed cerebrovascular diseases caused after subarachnoid hemorrhage, and cerebral vasospasm and transient ischemic attack caused after brain surgery operations and intervention treatment.

A therapeutic and / or preventing agent for a disease due to vascular constriction or vasodilation comprising a EDG-5 modulator. Since EDG-5 modulator specifically binds EDG-5 and shows antagonistic or agonistic action, EDG-5 antagonist is useful for treating and / or preventing for a disease due to vascular constriction, for example, cerebrovascular spasmodic disorder after subarachnoid hemorrhage or stroke, cardiovasucular spasmodic disorder, hypertension, renal disease, cardiac infarction, cardiac angina, arrhythmia, facilitation of the portal blood pressure involved in liver cirrhosis, varicosity involved in liver cirrhosis and the like, or EDG-5 agonist is useful for treating and / or preventing for a disease due to vasodilation of blood vessels, for example, chronic headache (such as migraine, tension-type headache, mixed-type headache thereof, or migrainous neuralgia), haemorrhoid, congestive disorder and the like.